<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630460</url>
  </required_header>
  <id_info>
    <org_study_id>UCHC03-008CMD</org_study_id>
    <nct_id>NCT01630460</nct_id>
  </id_info>
  <brief_title>Genetic and Functional Analysis of Craniometaphyseal Dysplasia (CMD)</brief_title>
  <acronym>CMD</acronym>
  <official_title>Identification of Mutations That Lead to Craniometaphyseal Dysplasia in Families and Isolated Cases and Studies of Cellular and Molecular Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CMD can be inherited in an autosomal dominant or recessive trait. CMD may also be caused by
      de novo mutations. The goal of this study is to identify genes and regulatory elements on
      chromosomes that are the cause for CMD. The investigators also study blood samples and tissue
      samples from patients to learn about the processes that lead to this disorder. The
      investigators long-term goal is to find mechanisms to slow down bone deposition in CMD
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CMD is a very rare bone disorder that affects mostly bones of the head (=cranial bones) but
      also long (=tubular) bones. Therefore, CMD has been added to the class of craniotubular bone
      disorders. There are a number of disorders in this group and sometimes they are difficult to
      distinguish. Typical signs for CMD are the lifelong bone deposition in bones of the face and
      head (=progressive craniofacial hyperostosis) and the widening of the ends of long bones
      (=metaphyseal flaring). Typical facial characteristics are wide-set eyes and a prominent jaw
      (=mandible). CMD is sometimes diagnosed in infants. The best way to confirm diagnosis is by
      molecular genetics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of genetic elements</measure>
    <time_frame>at time of identification</time_frame>
    <description>The goal is to identify relevant genes or genetic elements that cause the disease or contribute to the disease progression and severity.</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Craniometaphyseal Dysplasia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva, blood, bone tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with diagnosed CMD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CMD; unaffected individuals only if part of a participating CMD family

        Exclusion Criteria:

          -  No CMD; unaffected individuals only as part of a participating CMD family
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernst J Reichenberger, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ernst J Reichenberger, PhD</last_name>
    <phone>860-679-2062</phone>
    <email>reichenberger@uchc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernst J Reichenberger, PhD</last_name>
      <phone>860-679-2062</phone>
      <email>reichenberger@uchc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://health.uconn.edu/reichenberger-lab/</url>
    <description>study website</description>
  </link>
  <results_reference>
    <citation>Dutra EH, Chen IP, McGregor TL, Ranells JD, Reichenberger EJ. Two novel large ANKH deletion mutations in sporadic cases with craniometaphyseal dysplasia. Clin Genet. 2012 Jan;81(1):93-5. doi: 10.1111/j.1399-0004.2011.01700.x.</citation>
    <PMID>22150416</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen IP, Wang L, Jiang X, Aguila HL, Reichenberger EJ. A Phe377del mutation in ANK leads to impaired osteoblastogenesis and osteoclastogenesis in a mouse model for craniometaphyseal dysplasia (CMD). Hum Mol Genet. 2011 Mar 1;20(5):948-61. doi: 10.1093/hmg/ddq541. Epub 2010 Dec 13.</citation>
    <PMID>21149338</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen IP, Wang CJ, Strecker S, Koczon-Jaremko B, Boskey A, Reichenberger EJ. Introduction of a Phe377del mutation in ANK creates a mouse model for craniometaphyseal dysplasia. J Bone Miner Res. 2009 Jul;24(7):1206-15. doi: 10.1359/jbmr.090218.</citation>
    <PMID>19257826</PMID>
  </results_reference>
  <results_reference>
    <citation>Reichenberger E, Chen IP. Craniometaphyseal Dysplasia, Autosomal Dominant. 2007 Aug 27 [updated 2015 Jan 15]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviewsÂ® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from http://www.ncbi.nlm.nih.gov/books/NBK1461/</citation>
    <PMID>20301634</PMID>
  </results_reference>
  <results_reference>
    <citation>Reichenberger E, Tiziani V, Watanabe S, Park L, Ueki Y, Santanna C, Baur ST, Shiang R, Grange DK, Beighton P, Gardner J, Hamersma H, Sellars S, Ramesar R, Lidral AC, Sommer A, Raposo do Amaral CM, Gorlin RJ, Mulliken JB, Olsen BR. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001 Jun;68(6):1321-6. Epub 2001 Apr 16.</citation>
    <PMID>11326338</PMID>
  </results_reference>
  <results_reference>
    <citation>Hu Y, Chen IP, de Almeida S, Tiziani V, Do Amaral CM, Gowrishankar K, Passos-Bueno MR, Reichenberger EJ. A novel autosomal recessive GJA1 missense mutation linked to Craniometaphyseal dysplasia. PLoS One. 2013 Aug 12;8(8):e73576. doi: 10.1371/journal.pone.0073576. eCollection 2013.</citation>
    <PMID>23951358</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UConn Health</investigator_affiliation>
    <investigator_full_name>Ernst Reichenberger</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <keyword>Craniometaphyseal dysplasia</keyword>
  <keyword>bone</keyword>
  <keyword>hyperostosis</keyword>
  <keyword>osteoblast</keyword>
  <keyword>osteoclast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Hypertelorism</mesh_term>
    <mesh_term>Hyperostosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

